Key Points
- CEO Daniel Chard bought 17,678 shares on March 20 at an average price of $10.11 for roughly $178,725, leaving him with 17,678 shares (disclosed in an SEC filing and noted as an "∞" increase from prior holdings).
- Medifast recently beat quarterly estimates (EPS -$0.55 vs -$0.76; revenue $75.1M vs $71.4M) but remains unprofitable with negative margins and has set FY2026 guidance of -2.75 to -1.55 EPS; the stock has a $106.7M market cap and an average analyst rating of "Reduce" (target $12).
Medifast Inc (NYSE:MED - Get Free Report) CEO Daniel Chard bought 17,678 shares of the company's stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average price of $10.11 per share, for a total transaction of $178,724.58. Following the acquisition, the chief executive officer directly owned 17,678 shares in the company, valued at approximately $178,724.58. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Medifast Price Performance
Medifast stock opened at $9.71 on Friday. Medifast Inc has a fifty-two week low of $9.22 and a fifty-two week high of $15.46. The firm has a fifty day moving average price of $10.72 and a two-hundred day moving average price of $11.67. The firm has a market cap of $106.70 million, a price-to-earnings ratio of -5.68 and a beta of 0.52.
Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.21. The company had revenue of $75.10 million for the quarter, compared to the consensus estimate of $71.40 million. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.Medifast has set its FY 2026 guidance at -2.750--1.55 EPS and its Q1 2026 guidance at -0.700--0.15 EPS. As a group, sell-side analysts expect that Medifast Inc will post 0.51 earnings per share for the current year.
Institutional Trading of Medifast
A number of institutional investors and hedge funds have recently modified their holdings of MED. Peapod Lane Capital LLC raised its stake in shares of Medifast by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 88,164 shares of the specialty retailer's stock valued at $1,205,000 after purchasing an additional 970 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Medifast by 103.1% during the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer's stock worth $32,000 after buying an additional 1,187 shares in the last quarter. Man Group plc increased its holdings in Medifast by 0.6% in the 2nd quarter. Man Group plc now owns 198,156 shares of the specialty retailer's stock valued at $2,784,000 after buying an additional 1,200 shares during the period. JPMorgan Chase & Co. increased its holdings in Medifast by 2.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 53,341 shares of the specialty retailer's stock valued at $749,000 after buying an additional 1,316 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in shares of Medifast by 261.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer's stock valued at $28,000 after buying an additional 1,448 shares in the last quarter. 95.51% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
MED has been the subject of several research reports. Stephens reduced their price objective on Medifast from $15.00 to $12.00 and set an "equal weight" rating for the company in a research report on Thursday, February 19th. Wall Street Zen raised shares of Medifast from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Finally, Weiss Ratings restated a "sell (d)" rating on shares of Medifast in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and an average target price of $12.00.
Read Our Latest Stock Analysis on MED
Medifast Company Profile
(
Get Free Report)
Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.
Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
